Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Jan 4:11:2.
doi: 10.1186/1479-5876-11-2.

JTM's Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section

Editorial

JTM's Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section

Adrian Bot et al. J Transl Med. .

Abstract

For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor Immunology and Biological Cancer Therapy. Under the editorial leadership of Dr. Pedro Romero and with the direct support of the Society for Immunotherapy of Cancer (SITC), this section enriched the communication between basic immunological sciences and the clinical investigation arena in oncology. We are re-launching this Section of JTM, now entitled Immunobiology and Immunotherapy, succeeding Tumor Immunology and Biological Cancer Therapy. While aiming to build on the editorial success and focus of its predecessor, this novel Section will have a broader scope, hosting translational immunology topics pertaining to immunotherapy beyond oncology, including disciplines such as inflammation, autoimmunity, transplantation, metabolic disorders and others. As the vision of this re-launched Section of JTM broadens up to serve a communication need for translational immunologists involved with immunotherapy irrespectively of the therapeutic area, a novel and focused journal entitled Journal for Immunotherapy of Cancer (JITC) has just been initiated, sponsored by the SITC.

PubMed Disclaimer

Similar articles

References

    1. Soc Immunother Cancer. http://www.sitcancer.org/
    1. Romero P, Fox BA. iSBTc Executive Office. Announcing the tumor immunology and biological cancer therapy section (edited by iSBTc) of the Journal of Translational Medicine. J Transl Med. 2009;7:80. doi: 10.1186/1479-5876-7-80. - DOI - PMC - PubMed
    1. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520–6. doi: 10.1158/1078-0432.CCR-10-3126. - DOI - PubMed
    1. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805–12. doi: 10.1038/nrc3153. - DOI - PMC - PubMed
    1. J Immunother Cancer. http://www.immunotherapyofcancer.org/

Publication types

LinkOut - more resources